The global plasma fractionation market, valued at USD 29.83 billion in 2025, is on track for substantial expansion in the coming decade. The market is projected to grow at a CAGR of 6.70% from 2026 to 2035, ultimately reaching an estimated value of USD 57.06 billion by 2035. This growth is primarily fueled by the accelerating demand for plasma-derived therapies used in treating a broad spectrum of chronic and life-threatening medical conditions. These include immunodeficiency disorders, hemophilia, autoimmune diseases, neurological disorders, and respiratory conditions.In the first paragraph, the plasma fractionation market continues to gain momentum as global healthcare systems increasingly depend on plasma-derived medicinal products (PDMPs) to support critical patient needs. Plasma fractionation, the process of separating plasma proteins such as immunoglobulins, albumin, and coagulation factors, plays a vital role in modern medicine. With the prevalence of chronic diseases on the rise and advancements in plasma collection technologies, the demand for safe, effective plasma-based therapies is reaching unprecedented levels.
Request your complimentary sample report featuring the complete TOC
One of the major market drivers is the rising incidence of immune disorders and bleeding disorders worldwide. Immunoglobulins, which constitute a significant share of plasma-derived products, are witnessing surging demand due to their widespread use in immunodeficiency treatments, inflammatory conditions, and neurological diseases. As clinical research expands and new therapeutic indications emerge, the immunoglobulin segment is expected to remain a dominant force within the market.
Additionally, increased awareness regarding plasma donation has significantly improved plasma collection volumes globally. Regulatory support and investments in plasma collection centers, especially across North America and Europe, are contributing to a steady supply chain. The development of advanced fractionation facilities and improvements in purification technologies are further enhancing production efficiency and product safety.
The COVID-19 pandemic also highlighted the importance of plasma therapies, boosting research into convalescent plasma and other plasma-based approaches. Although emergency-related demand has normalized, the heightened focus on plasma science continues to support market growth.
Regionally, North America remains the largest plasma fractionation market, driven by strong healthcare infrastructure, robust plasma collection networks, and high adoption of plasma-derived therapies. Europe follows closely, supported by favorable regulations and increased research activities. Meanwhile, Asia-Pacific is emerging as a key growth hub due to rising healthcare expenditure, expanding diagnostic capabilities, and increasing patient awareness.
As healthcare demand intensifies and the clinical applications of plasma-derived therapies expand, the global plasma fractionation market is well-positioned to witness sustained upward momentum. With its projected valuation of USD 57.06 billion by 2035, the sector will continue to play a pivotal role in advancing global therapeutic capabilities and improving patient outcomes.